The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Targeting FGG alleviates cholestatic fibrosis by inhibiting hepatic stellate cell activation and regulating macrophage homeostasis
Open accessAbstract
BACKGROUND & AIMS: Cholestatic liver injury is a serious pathological process with limited treatment options. The function of fibrinogen gamma chain (FGG) in the liver is not well defined. This study aims to explore the role of FGG in the progression of cholestatic liver fibrosis, and to find a new target for the treatment of cholestatic liver fibrosis. RESULTS: A BDL induced mouse model and LX2 cell line, as well as a co-culture system of LX2 and THP-1, were used. Gene expression, cell activation and polarization were evaluated by qRT-PCR, Western Blot, RNA-seq, and immunofluorescence. 4-Octyl itaconate (OI) was used to block the M2 polarization, and an AEAA-modified lipid nanoparticle (LNP) was developed as a platform for targeted delivery of siFGG, and its therapeutic efficacy was evaluated in vitro and in vivo. In the BDL mouse, FGG expression was significantly increased and mainly localized to activated hepatic stellate cells (HSCs). In vitro experiments confirmed that FGG directly regulated the activation state of HSCs. Overexpression of FGG in mice significantly promoted the development of liver fibrosis. Further studies revealed that FGG specifically promoted macrophage polarization toward the M2 phenotype. Co-culture experiments demonstrated that FGG was a key factor driving M2 polarization of macrophages. The siFGG delivered by AEAA-LNP effectively knocked down the expression of FGG, thereby inhibiting HSC activation, disrupting the crosstalk between HSC and M2 macrophages, and ultimately significantly alleviating BDL induced liver fibrosis in vitro and in vivo. CONCLUSIONS: This study identifies FGG as a key fibrosis promoter that acts through simultaneous HSC activation and M2 macrophage polarization. Targeting FGG with a novel AEAA-LNP system offers a potent dual-mechanism therapy for liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024 · cited 1×
“Upon activation, HSCs differentiate into α-SMA positive myofibroblasts, which secrete excessive extracellular matrix components and promote collagen deposition, ultimately resulting in pathological scar tissue accumulation [9, 10].”
Macrophages: versatile players in renal inflammation and fibrosis
Tang, P. M.-K., Nikolic-Paterson, D. J., & Lan, H.-Y. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0110-2 · Cited by 1,033 · cited 1×
“Macrophages demonstrate complex and dynamic dual roles in fibrotic processes across various organ systems [41–43].”
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803 · cited 1×
“In the context of liver fibrosis, a reciprocal interaction exists between macrophages and HSCs that collectively influences disease progression [48], though the precise regulatory mechanisms remain incompletely characterized.”
Zhao, S., Mi, Y., Guan, B., Zheng, B., Wei, P., Gu, Y., Zhang, Z., Cai, S., Xu, Y., Li, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00991-2 · Cited by 778
Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer
Buechler, M. B., Fu, W., & Turley, S. J. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.021 · Cited by 494
Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages
Runtsch, M. C., Angiari, S., Hooftman, A., Wadhwa, R., Zhang, Y., Zheng, Y., Spina, J. S., Ruzek, M. C., Argiriadi, M. A., McGettrick, A. F., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.002 · Cited by 323
Self-citationMa, P.-F., Gao, C.-C., Yi, J., Zhao, J.-L., Liang, S.-Q., Zhao, Y., Ye, Y.-C., Bai, J., Zheng, Q.-J., Dou, K.-F., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.022 · Cited by 284 · cited 1×
“While some studies indicate that M1 polarization can promote fibrosis through enhanced secretion of inflammatory mediators [44, 45], other investigations demonstrate that M2 polarization similarly contributes to fibrotic progression [13, 18, 46, 47].”
Yang, W., He, H., Wang, T., Su, N., Zhang, F., Jiang, K., Zhu, J., Zhang, C., Niu, K., Wang, L., et al. (2021) · Hepatology · doi:10.1002/hep.31987 · Cited by 250
MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program
Wang, Y., Zhang, L., Wu, G.-R., Zhou, Q., Yue, H., Rao, L.-Z., Yuan, T., Mo, B., Wang, F.-X., Chen, L.-M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb6075 · Cited by 227
Self-citation
Cited by
Still being checked.
Metadata
- Authors
- Wei, Q., Li, M., Yang, Q., Ren, M., Liu, X., Cai, X., Shi, J., Huang, C., Wang, Y., Zhang, Y., Yu, D., Guo, W., & Zhang, S.
- Affiliations
- First Affiliated Hospital of Zhengzhou University (CN)
- Xuzhou Central Hospital (CN)
- Corresponding author
- Yu, Dongsheng
- Guo, Wenzhi
- Zhang, Shuijun
- Venue
- Journal of Nanobiotechnology
- Published
- 2026-04-18
- Volume
- 24
- Issue
- 1
- ISSN
- 1477-3155 (ISSN-L)
- PMC
- PMC13227837
- OpenAlex
- W7154844307
- Cited by
- 0
- References
- 51
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor, 45 d)
- Locations
- Journal of Nanobiotechnology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- New Round of Xuzhou "Pengcheng Talent Program"-High-level Healthcare Talent Recruitment and Development Project (2025QZ004)
- National Natural Science Foundation of China (82170670)
- Medical Science and Technology Program of Henan (SB201901045)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- fibrinogen gamma chain, cholestatic liver fibrosis, hepatic stellate cell activation, M2 macrophage polarization, hepatic macrophages, bile duct ligation, siRNA delivery, lipid nanoparticles
- MeSH terms
- Animals, Cell Line, Cholestasis, Disease Models, Animal, Homeostasis, Humans, Liver Cirrhosis, Macrophages, Male, Mice, Inbred C57BL, Coculture Techniques, Mice, Hepatic Stellate Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting FGG alleviates cholestatic fibrosis by inhibiting hepatic stellate cell activation and regulating macrophage homeostasis. https://app.cochat.ai/papers/10.1186/s12951-026-04432-z
- The paper
- Wei, Q., Li, M., Yang, Q., Ren, M., Liu, X., Cai, X., Shi, J., Huang, C., Wang, Y., Zhang, Y., Yu, D., Guo, W., & Zhang, S. (2026). Targeting FGG alleviates cholestatic fibrosis by inhibiting hepatic stellate cell activation and regulating macrophage homeostasis. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-026-04432-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.